Subject(s)
Antineoplastic Agents/therapeutic use , Body Height/drug effects , Body Weight/drug effects , Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Adolescent , Anthropometry , Child , Female , Humans , Male , Precursor Cell Lymphoblastic Leukemia-Lymphoma/physiopathology , Remission Induction , Sex Factors , Time FactorsSubject(s)
Antineoplastic Combined Chemotherapy Protocols/adverse effects , Leukemia, Lymphoid/drug therapy , Lung/physiopathology , Respiration/drug effects , Adolescent , Adult , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Child , Female , Humans , Leukemia, Lymphoid/physiopathology , MaleABSTRACT
The in vivo effect of thymus factor X (TFX) on the E-rosetting capacity, the absolute peripheral blood lymphocytes and T-cell number per microliter, the skin test reactivity to recall antigens, and the immunoglobulin production was evaluated in 20 children with acute lymphoblastic leukaemia. The in vitro effect of TFX was also tested. The mean percentage of E-rosettes in these patients increased from 50 to 64%. Although absolute peripheral blood lymphocyte and T-cell number per microliter rose significantly, the mean values did not reach those in healthy children. The tests with recall antigens were positive in 13% of patients prior to immunotherapy and 32% following the therapy. The influence of immunotherapy on infectious episodes and on the stabilisation of remission was also evaluated. TFX in vivo appears to restore immunocompetence, decrease infections, and prolong remissions in children with ALL in remission.